Table 4:

Wilcoxon rank sum test for longitudinal persistence of meningeal enhancement versus demographic and clinical factorsa

On Treatment (n = 25)Not on Treatment (n = 6)Progressive MS (n = 10)Nonprogressive MS (n = 21)EDSS Progressor at 1 yrb (n = 7)EDSS Nonprogressor at 1 yrb (n = 24)
Total No. of overall foci persisting at 1 yr per subject9 (1–24)9 (1–15)8 (1–24)9 (1–15)12 (1–15)7.5 (1–24)c
Total No. of subarachnoid spread/fill foci persisting at 1 yr per subject2 (0–9)2 (0–6)2 (0–9)2 (0–9)5 (1–9)2 (0–9)
Total No. of subarachnoid nodular foci persisting at 1 yr per subject0 (0–2)0 (0–1)0 (0–0)0 (0–2)c0 (0–0)0 (0–2)
Total No. of vessel wall foci persisting at 1 yr per subject3 (0–11)3.5 (1–6)2 (0–6)3 (0–11)3 (0–11)3 (0–7)
Total No. of dural foci persisting at 1 yr per subject1 (0–9)1 (0–6)1 (0–9)1 (0–6)1 (0–6)1 (0–9)

  • ↵a Median values are listed with the range of observed values in parentheses.

  • ↵b Criteria for EDSS progressor status is listed in the “Materials and Methods” section.

  • ↵c P < .05.